The New England journal of medicine
-
Comment Letter
Open-Source Automated Insulin Delivery in Type 1 Diabetes.
-
Randomized Controlled Trial
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. ⋯ Olpasiran therapy significantly reduced lipoprotein(a) concentrations in patients with established atherosclerotic cardiovascular disease. Longer and larger trials will be necessary to determine the effect of olpasiran therapy on cardiovascular disease. (Funded by Amgen; OCEAN[a]-DOSE ClinicalTrials.gov number, NCT04270760.).